Skip to Main content Skip to Navigation
Journal articles

Evidence for a direct and functional interaction between the regulators of G protein signaling-2 and phosphorylated C terminus of cholecystokinin-2 receptor.

Abstract : Signaling of G protein-coupled receptors (GPCRs) is regulated by different mechanisms. One of these involves regulators of G protein signaling (RGS), which are diverse and multifunctional proteins that bind to active Galpha subunits of G proteins and act as GTPase-activating proteins. Little is known about the molecular mechanisms that govern the selective use of RGS proteins in living cells. We first demonstrated that CCK2R-mediated inositol phosphate production, known to be G(q)-dependent, is more sensitive to RGS2 than to RGS4 and is insensitive to RGS8. Both basal and agonist-stimulated activities of the CCK2R are regulated by RGS2. By combining biochemical, functional, and in silico structural approaches, we demonstrate that a direct and functional interaction occurs between RGS2 and agonist-stimulated cholecystokinin receptor-2 (CCK2R) and identified the precise residues involved: phosphorylated Ser434 and Thr439 located in the C-terminal tail of CCK2R and Lys62, Lys63, and Gln67, located in the N-terminal domain of RGS2. These findings confirm previous reports that RGS proteins can interact with GPCRs to modulate their signaling and provide a molecular basis for RGS2 recognition by the CCK2R.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00408743
Contributor : Marie Francoise Simon <>
Submitted on : Monday, August 3, 2009 - 9:32:14 AM
Last modification on : Thursday, June 4, 2020 - 10:24:02 AM

Identifiers

Collections

Citation

Ingrid Langer, Irina Tikhonova, Cyril Boulègue, Jean-Pierre Estève, Sébastien Vatinel, et al.. Evidence for a direct and functional interaction between the regulators of G protein signaling-2 and phosphorylated C terminus of cholecystokinin-2 receptor.. Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2009, 75 (3), pp.502-13. ⟨10.1124/mol.108.051607⟩. ⟨inserm-00408743⟩

Share

Metrics

Record views

235